REGENXBIO Inc.
RGNXNASDAQHealthcareBiotechnology
As of Oct 27, 2026 close
- Market cap
- $349.91M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.46$16.19
- Volume (live)
- -
- Avg. volume (3M)
- 1.47M
REGENXBIO (RGNX) Stock Price & Financial Analysis
REGENXBIO Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $6.46 - $6.78 |
|---|---|
| 52-Week High | $16.19 |
| 52-Week Low | $5.46 |
| Open | $6.54 |
| Volume (last close) | 1.22M |
| Average Volume (3M) | 1.47M |
| Revenue (TTM) | 174.48M |
|---|---|
| Net Income (TTM) | -196.43M |
| Free Cash Flow (TTM) | -249.67M |
| EPS (TTM) | −$3.76 |
| Profit Margin | -112.58% |
| Operating Margin | -94.08% |
| Return on Equity (ROE) | -273.72% |
| Debt to Equity | 0.96 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 349.91M |
|---|---|
| Shares Outstanding | 53.02M |
| Price to Sales (P/S) | 2.01 |
| Price to Book (P/B) | 4.88 |
| EV/EBITDA | -2.97 |
| 50-Day MA | $8.63 |
|---|---|
| 200-Day MA | $9.48 |
| 1-Year Change | −43.00% |
Source: Market prices and company fundamentals. Data as of Oct 27, 2026. Data sources and methodology
REGENXBIO at a Glance
As of the Oct 27, 2026 close, REGENXBIO (RGNX) has a market capitalization of $349.91M. The stock trades at 2.0× sales. Over the trailing twelve months it lost $196.43M on revenue of $174.48M and burned $249.67M of free cash flow. Revenue grew 12.0% year over year.
As of its latest reported balance sheet, it holds $36.49M in cash and securities against $68.95M of debt, a net debt position of $32.46M.
REGENXBIO does not currently pay a dividend.
The share price is down 43.0% over the past year. At $6.60 (the Oct 27, 2026 close) it sits near the bottom of its 52-week range of $5.46 to $16.19, below its 200-day moving average of $9.48.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $21.42, 224.5% above the Oct 27, 2026 close.
Frequently Asked Questions About REGENXBIO
What is the current stock price for RGNX?
As of the Oct 27, 2026 close, RGNX stock trades at $6.60. The 52-week range is $5.46–$16.19, with a day range of $6.46–$6.78.
What is the P/E ratio for RGNX?
The P/E ratio (Price-to-Earnings) for RGNX is shown in the Key Statistics section. This valuation metric helps compare REGENXBIO Inc. to industry peers.
Does RGNX pay dividends?
REGENXBIO does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RGNX?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for RGNX is Buy. The average 12-month price target is $21.42, a 224.5% upside from the Oct 27, 2026 close of $6.60.
What is the market cap of RGNX?
As of the Oct 27, 2026 close, REGENXBIO's market capitalization is $349.9M, classifying it as a small-cap company. REGENXBIO operates in the Healthcare sector within the Biotechnology industry.